Clinical Trials
Istari Oncology is committed to the successful clinical development and registration of PVSRIPO and other technologies for the treatment of cancer.
PVSRIPO
FDA granted PVSRIPO Breakthrough Therapy and Orphan Drug Designation in 2016.
Current Clinical Trials
- RecruitingRecurrent Glioblastoma:
LUMINOS-101: PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma
ATC
We are currently evaluating D2C7 in a dose escalation Phase 1 study, which began in 2014. The study is scheduled to end in 2020. A combination trial, D2C7 plus atezolizumab, is currently enrolling.
Current Clinical Trials
- RecruitingRecurrent Glioblastoma:
D2C7 for Adult Patients With Recurrent Malignant Glioma
D2C7 With Atezolizumab for Recurrent Gliomas